Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.80 |
| ▸ | CCR5 | P51681 | 19/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085867 | 0.95 | CXCR3 (0.82) | CXCR3CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2084666 | 0.89 | CXCR3 (1.00) | CXCR3CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2085182 | 0.88 | CXCR3 (0.80) | CXCR3CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2082357 | 0.87 | CXCR3 (0.85) | CXCR3CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6012909 | 0.86 | CXCR3 (0.69) | CXCR3CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2085434 | 0.86 | CXCR3 (0.87) | CXCR3CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6012345 | 0.86 | CXCR3 (0.68) | CXCR3CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6612247 | 0.85 | CXCR3 (0.92) | CXCR3CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6012582 | 0.84 | CXCR3 (0.66) | CXCR3CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6616234 | 0.84 | CXCR3 (0.74) | CXCR3CCR5CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052612-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-1889622-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052612-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | CXCR3, CFTR, CXCR1 | CXCR3 1/4885CCR5 10/4885CYP3A4 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.